3100 Hansen Way
10 articles with Varian Medical
6/5/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Varian (NYSE: VAR) today announced its Halcyon ™ 2.0 treatment system has been approved by the China National Medical Products Administration (NMPA), which allows the company to market this cancer treatment system in China .
Varian (NYSE: VAR) today announced it was selected to equip the new Ethos Personalized Adaptive Therapy Center in Phoenix, Arizona , and help launch a new era in cancer treatment for patients in the region. Ethos™ therapy provides the ability to personalize the patient's radiation treatments based on their anatomy and the tumor
Varian (NYSE: VAR) today announced it has received FDA 510(k) clearance for its Ethos ™ therapy, an Adaptive Intelligence ™ solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to
NYPC is expected to treat 1,400 patients annually, including most children in New York City with solid tumors, delivering the most advanced form of cancer radiation treatment currently available.
Varian (NYSE: VAR) today announced that its executive staff will be meeting with analysts and investors at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Chicago on Monday, September 16, 2019 at 2:00 p.m. Central Time.
It incorporates patient safety, quality, efficiency, and surface-guidance features in an automated workflow solution for surface-guided radiation therapy
Through the partnership, Varian made available a TrueBeam™ system to the IAEA's Dosimetry Laboratory in Seibersdorf, Austria, which will enhance the laboratory's capacity to provide support in the areas of calibration and audit dosimetry services and relevant training.
Collaboration with Tennessee Oncology Aims to Improve Access to Care Across Rural Patient Populations
Proton Clinical Research Center of the Shandong Cancer Hospital First APAC Member of FlashForward Consortium
The Consortium now includes 15 institutions and is focused on preclinical research, clinical implementation, and advocacy efforts for FLASH Therapy.